JCR Pharmaceuticals Co., Ltd. (JCRRF)
OTCMKTS · Delayed Price · Currency is USD
4.170
0.00 (0.00%)
At close: Jan 30, 2026
JCR Pharmaceuticals Revenue
JCR Pharmaceuticals had revenue of 8.99B JPY in the quarter ending December 31, 2025, a decrease of -2.52%. This brings the company's revenue in the last twelve months to 37.55B, up 7.17% year-over-year. In the fiscal year ending March 31, 2025, JCR Pharmaceuticals had annual revenue of 33.07B, down -22.86%.
Revenue (ttm)
37.55B JPY
Revenue Growth
+7.17%
P/S Ratio
2.25
Revenue / Employee
38.04M JPY
Employees
987
Market Cap
538.71M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 33.07B | -9.80B | -22.86% |
| Mar 31, 2024 | 42.87B | 8.53B | 24.83% |
| Mar 31, 2023 | 34.34B | -16.74B | -32.77% |
| Mar 31, 2022 | 51.08B | 21.00B | 69.79% |
| Mar 31, 2021 | 30.09B | 5.30B | 21.40% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
JCR Pharmaceuticals News
- 16 days ago - JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026 - Business Wire
- 5 weeks ago - JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease - Business Wire
- 4 months ago - JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology - Business Wire
- 4 months ago - JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets - Business Wire
- 4 months ago - JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - Business Wire
- 5 months ago - JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program - Business Wire
- 5 months ago - JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives - Business Wire